{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:42Z","timestamp":1791335622147,"version":"4.3.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":616,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1093\/annonc\/mdy086","type":"journal-article","created":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T20:08:27Z","timestamp":1520107707000},"page":"1258-1265","source":"Crossref","is-referenced-by-count":101,"title":["Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical\u2013pathological features and intratumor heterogeneity over time"],"prefix":"10.1016","volume":"29","author":[{"given":"G.","family":"Pasello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Zago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lunardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Urso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vlacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mencoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.L.","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pezzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Vuljan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Del Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1093\/annonc\/mdy086_bb0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1093\/annonc\/mdy086_bb0015","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00262-011-1103-6","article-title":"Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma","volume":"60","author":"Bograd","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1093\/annonc\/mdy086_bb0020","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"10.1093\/annonc\/mdy086_bb0025","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdy086_bb0030","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/mdy086_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1093\/annonc\/mdy086_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2015.07.014","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma","volume":"90","author":"Yamagishi","year":"2015","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdy086_bb0045","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"2","key":"10.1093\/annonc\/mdy086_bb0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/713774061","article-title":"Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells","volume":"9","author":"Eppihimer","year":"2002","journal-title":"Microcirculation"},{"issue":"49","key":"10.1093\/annonc\/mdy086_bb0055","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1093\/annonc\/mdy086_bb0060","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioms is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy086_bb0065","doi-asserted-by":"crossref","first-page":"e0121071.","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdy086_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1093\/annonc\/mdy086_bb0075","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15S","key":"10.1093\/annonc\/mdy086_bb0080","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5795","key":"10.1093\/annonc\/mdy086_bb0085","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"15","key":"10.1093\/annonc\/mdy086_bb0090","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdy086_bb0095","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1158\/1078-0432.CCR-08-0133","article-title":"Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer","volume":"14","author":"Al-Shibli","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdy086_bb0100","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy086_bb0105","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(17)30191-2","article-title":"Immune checkpoint inhibitors in malignant pleural mesothelioma","volume":"18","author":"Ceresoli","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/5\/1258\/24831828\/mdy086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:40:21Z","timestamp":1624696821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419345508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0923753419345508"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy086","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}